James' World 2

Click the link below the picture

.

Would you be impressed by a car that gets 93 mpg? If the answer is yes, then you’re going to be impressed by the current Toyota Prius. While the current Prius may be EPA-rated for a “lowly” 57 mpg, it just completed a cross-country drive, from Los Angeles’ City Hall to New York’s City Hall, while averaging 93.1 MPG. That’s a 3,200-mile trip, so unlike a lot of fuel efficiency tests that take place over a few dozen or a few hundred miles, this one took place between two of America’s biggest cities, one on each coast. And yes, that’s a new fuel-efficiency world record, certified by Guinness.

How does a Toyota Prius nearly double its certified fuel efficiency? The single biggest factor is how it’s driven, or in this case, who is doing the driving. This hyper-efficient Prius owes its record-setting run to a gentleman named Wayne Gerdes, who publishes a website called CleanMPG.com and has a long history of setting efficiency records. The last time Wayne drove across the country, in a Kia Niro hybrid in 2016, he achieved a then-record 76.6 MPG. Wayne has also set records for driving a Volkswagen Passat TDI through all 48 contiguous states while averaging 68 MPG.

So Wayne Gerdes likes to break automotive efficiency records. And this time he chose the current Toyota Prius, which has already won a long list of accolades, including my personal assessment as the best car you can buy today, at least if you’re looking for the best combination of value, reliability, performance, safety, styling, and yes, fuel efficiency. It didn’t surprise me to see Wayne pair up with the current Prius to break another record. Still, getting an average of 93 mpg out of the car while crossing the U.S. is truly impressive.

Think about this — if Wayne was averaging 93 MPG, that means half the time he was doing better than that. It’s safe to assume he was seeing over 100 MPG on long stretches of road, and not just when going down hill. This is the ultimate form of hypermiling, which is what Wayne specializes in. If you read past accounts of how Wayne drives a car, you hear about the usual tactics, like being super-light on the throttle, keeping the vehicle’s speed down, and trying to time his arrival at stop lights so they’re green.

.

.

.

Click the link below for the article:

.

__________________________________________

Click the link below the picture

.

On behalf of the 55 million people worldwide who live with  Alzheimer’s disease, the millions more who shoulder the burden of care and loss, and the younger generations whose futures are clouded by the threat of this disease, we issue a call to action. 

The time is ripe. For the first time, we have an opportunity to defeat this disease, which robs so many otherwise healthy people of their memories and their identities and causes so much suffering and loss to them, their loved ones, and society at large.  

In recent years, scientists have made startling advances in their ability to detect Alzheimer’s disease in the early stages, when treatments are most effective. Drugs are now available that can slow the progress of the disease, having gone from the lab to pharmacy shelves, and more are in the pipeline. 

The arrival of these twin advances in testing and treatments has galvanized medical researchers, entrepreneurs and healthcare professionals. Several big pharmaceutical firms that had backed away from the disease, because it was so complex that it defied quick solutions, are once again making big investments. Biotech firms are working to commercialize new technologies, such as blood biomarker tests and cognitive tests that can help in diagnostics and screening. What’s more, regulators have shown a new willingness to move drugs quickly through the approval process, which is spurring innovation.

This good news brings a new challenge: getting these tests and treatments to the millions of people in all corners of the world who need them. We formed the Davos Alzheimer’s Collaborative (DAC) in part to address this challenge.

Part of this task involves bolstering our ability to detect Alzheimer’s early in the disease. Several blood tests that are currently on the market can measure telltale proteins, and more are due in the coming months. We need to make these tests cost-effective and plentiful. 

Even though much of the technology needed for early detection is already in place, policymakers are underestimating the resources and assistance that clinics, doctors’ offices and public-health officials will require to adopt and implement early detection.

Putting tools in the hands of consumers is another effective strategy that could be helpful in early detection. Digital assessment tools are now available that allow you to test yourself for cognitive impairment—whether it’s memory, judgment or orientation. Such tests can help manage the screening workload in clinics. 

We also need to raise public awareness about the new outlook for Alzheimer’s, so that people know there’s something they can do about the disease other than fear it. People should be asking their doctors, “How is my brain health? Is there a blood test I can take?” Doctors will need to figure out how to build Alzheimer’s testing into their routine clinical practice. DAC is helping them do exactly that. 

Rectifying inequities is critical. So far, researchers developing treatments and tests have focused on people of northern European descent, neglecting the rest of the world, where the vast majority of Alzheimer’s patients are to be found. This is unfair, and it is also bad science, because it leaves out information contained in the full panoply of human genetic diversity. Research organizations are making efforts to rectify this gap, but much remains to be done. 

Healthcare systems around the world, already strained by the growing prevalence of Alzheimer’s and other diseases, will need help in handling the new protocols for screening and treatment. 

To seize this global moment, we must work together. At present, the field of Alzheimer’s is fragmented. Academics work with their cohorts, businesses have their product strategies, governments focus on their own citizens. This compartmentalization is a wasted opportunity to pool our knowledge and scale our resources. 

Governments around the world need to step up their game. The U.S. National Institutes of Health spent about $400 million a year on Alzheimer’s disease in 2010; it now spends $3.7 billion. No other government or region comes close. Europe, China, India and other nations need to join the U.S., U.K. and others in the fight against this disease. 

The World Economic Forum and the Global CEO Initiative on Alzheimer’s Disease came together to form DAC, because we need an international organization that can coordinate an approach to Alzheimer’s disease that resembles the global effort to fight infectious disease. DAC was  modeled on organizations such as Gavi, the Vaccine Alliance; The Coalition for Epidemic Preparedness Innovations and The Global Fund, which were formed as mechanisms for battling malaria, polio, influenza and other infectious diseases around the world. 

Defeating Alzheimer’s will require a massive cooperative effort. DAC is already working to speed innovation and prepare healthcare systems to implement new technologies and strategies. We are enlisting corporate executives, government leaders and nongovernmental organizations in an effort to ease the burden of this disease and end the suffering it causes. 

In the following pages you will read about our efforts thus far to make health systems better able to detect the disease early, reach underserved populations and to find new, innovative ways of bringing more providers to the frontlines.

Leveraging what we are learning from around the world, we are calling on governments to increase their investments in research, healthcare and treatments. Working together, we can beat this disease rapidly and comprehensively. 

Alzheimer’s disease, the millions more who shoulder the burden of care and loss, and the younger generations whose futures are clouded by the threat of this disease, we issue a call to action. 

The time is ripe. For the first time, we have an opportunity to defeat this disease, which robs so many otherwise healthy people of their memories and their identities and causes so much suffering and loss to them, their loved ones and society at large.  

In recent years, scientists have made startling advances in their ability to detect Alzheimer’s disease in the early stages, when treatments are most effective. Drugs are now available that can slow the progress of the disease, having gone from the lab to pharmacy shelves, and more are in the pipeline. 

The arrival of these twin advances in testing and treatments has galvanized medical researchers, entrepreneurs and healthcare professionals. Several big pharmaceutical firms that had backed away from the disease, because it was so complex that it defied quick solutions, are once again making big investments. Biotech firms are working to commercialize new technologies, such as blood biomarker tests and cognitive tests that can help in diagnostics and screening. What’s more, regulators have shown a new willingness to move drugs quickly through the approval process, which is spurring innovation.

This good news brings a new challenge: getting these tests and treatments to the millions of people in all corners of the world who need them. We formed the Davos Alzheimer’s Collaborative (DAC) in part to address this challenge.

Part of this task involves bolstering our ability to detect Alzheimer’s early in the disease. Several blood tests that are currently on the market can measure telltale proteins, and more are due in the coming months. We need to make these tests cost-effective and plentiful. 

Even though much of the technology needed for early detection is already in place, policymakers are underestimating the resources and assistance that clinics, doctors’ offices and public-health officials will require to adopt and implement early detection.

Putting tools in the hands of consumers is another effective strategy that could be helpful in early detection. Digital assessment tools are now available that allow you to test yourself for cognitive impairment—whether it’s memory, judgment or orientation. Such tests can help manage the screening workload in clinics. 

We also need to raise public awareness about the new outlook for Alzheimer’s, so that people know there’s something they can do about the disease other than fear it. People should be asking their doctors, “How is my brain health? Is there a blood test I can take?” Doctors will need to figure out how to build Alzheimer’s testing into their routine clinical practice. DAC is helping them do exactly that. 

Rectifying inequities is critical. So far, researchers developing treatments and tests have focused on people of northern European descent, neglecting the rest of the world, where the vast majority of Alzheimer’s patients are to be found. This is unfair, and it is also bad science, because it leaves out information contained in the full panoply of human genetic diversity. Research organizations are making efforts to rectify this gap, but much remains to be done. 

Healthcare systems around the world, already strained by the growing prevalence of Alzheimer’s and other diseases, will need help in handling the new protocols for screening and treatment. 

To seize this global moment, we must work together. At present, the field of Alzheimer’s is fragmented. Academics work with their cohorts, businesses have their product strategies, governments focus on their own citizens. This compartmentalization is a wasted opportunity to pool our knowledge and scale our resources. 

Governments around the world need to step up their game. The U.S. National Institutes of Health spent about $400 million a year on Alzheimer’s disease in 2010; it now spends $3.7 billion. No other government or region comes close. Europe, China, India and other nations need to join the U.S., U.K. and others in the fight against this disease. 

The World Economic Forum and the Global CEO Initiative on Alzheimer’s Disease came together to form DAC, because we need an international organization that can coordinate an approach to Alzheimer’s disease that resembles the global effort to fight infectious disease. DAC was  modeled on organizations such as Gavi, the Vaccine Alliance; The Coalition for Epidemic Preparedness Innovations and The Global Fund, which were formed as mechanisms for battling malaria, polio, influenza and other infectious diseases around the world. 

Defeating Alzheimer’s will require a massive cooperative effort. DAC is already working to speed innovation and prepare healthcare systems to implement new technologies and strategies. We are enlisting corporate executives, government leaders and nongovernmental organizations in an effort to ease the burden of this disease and end the suffering it causes. 

In the following pages you will read about our efforts thus far to make health systems better able to detect the disease early, reach underserved populations and to find new, innovative ways of bringing more providers to the frontlines.

Leveraging what we are learning from around the world, we are calling on governments to increase their investments in research, healthcare and treatments. Working together, we can beat this disease rapidly and comprehensively. 

.

.

.

Click the link below for the article:

.

__________________________________________

Click the link below the picture

.

Friendships are meant to be a sanctuary—a place of happiness, trust and support. But when a friend gaslights you, this safe space turns into an emotional battlefield, leaving you questioning your reality and sense of self. To add insult to injury, gaslighting is often difficult to identify as it’s a subtle and lowkey form of constant and progressive manipulation—gradually pulling you away from your real world toward self-doubt and guilt.

Gaslighting is a manipulation tactic where the victim is made to doubt their reality and feel crazy. It often involves key elements such as denying facts upfront, twisting words and their meanings, or making you feel overly sensitive. While breaking free is tough, here are five strategic ways to start.

1. Recognize Their Patterns

The first step in addressing gaslighting is recognizing it—understanding that someone is warping your sense of reality. A 2024 study published in the journal Current Approaches in Psychiatry shows that gaslighting can happen in various relationships—from romantic to social to political.

It also suggests that gaslighting is often driven by power imbalances, personality traits and how much individuals depend on one another. Phrases like “you’re imagining things” or “that never happened” are common red flags. Dr. Robin Stern, co-founder and associate director of the Yale Center for Emotional Intelligence and a pioneering psychologist in this field, exemplifies multiple scenarios of gaslighting in her book—The Gaslight Effect (2007). She underscores that recognizing early signs is essential to counter this emotional manipulation.

You might notice constant manipulation, where your friend dismisses your feelings as overreactions or accuses you of being too sensitive. Pay keen attention to see how often you are left questioning your own perceptions after normal day-to-day conversations and if you end up feeling chronically unsettled.

While genuine friendship also involves moments of brutal and unsettling honesty, a gaslit friendship may affect your public confidence. Recognizing these patterns is crucial for maintaining healthy and authentic friendships. When you repeatedly face gaslighting, you might internalize it, causing unfounded self-doubt to grow. Awareness of these tactics is your first line of defense in reclaiming your sense of self.

.

Does your friend’s support turn into strain, and loyalty feel like a burden? Here’s how to navigate … [+]  Getty

.

.

Click the link below for the article:

.

__________________________________________

Click the link below the picture

.

.

.

.

Click the link below for the article:

.

__________________________________________

Click the link below the picture

.

On Sunday, Rev. Amos C. Brown led service at Third Baptist Church of San Francisco, as he has on most Sundays since becoming pastor there in 1976.

Wearing a hoodie bearing the images of Rev. Martin Luther King Jr., Nelson Mandela, Kwame Ture, and John Lewis, along with the words “GOOD TROUBLE,” he called the congregation to fix their “hearts, minds, and spirits on prayer.” He prayed, by name, for over 30 members of the church who were “sick and shut in.”

Before Brown read from Hebrews 12:1-3, a congregant handed him a note to let him know that President Joe Biden was stepping out of the race for reelection. He read from the verse, saying, “seeing we also are compassed about with so great a cloud of witnesses, let us lay aside every weight, and the sin which doth so easily beset us, and let us run with patience the race that is set before us.”

Then, after the service, Brown received a phone call from another member who was absent that Sunday: Vice President Kamala Harris, who was preparing to run a very different type of race.

“She said to me, ‘Pastor, I called because I want you to pray for me, [my husband] Doug, this country’ — and finally she said — ‘and the race I am intending to run for president,’” Brown told Sojourners on Monday. “We exchanged pleasantries, I congratulated her because she’ll be a great president, and we had prayer. She was so gracious and thankful that I took the time.”

Brown is no stranger to speaking faithfully into high-pressure political moments — as a younger man, he was one of Rev. Martin Luther King Jr.’s few students at Morehouse College. Brown, a veteran Civil Rights activist, has served at Third Baptist since 1976. He also served as a delegate to the United Nations World Conference Against Racism in 2001, is the president of the San Francisco chapter of the NAACP, and served as vice chair of California’s Reparations Task Force.

Harris, who earned enough delegate support by Monday to become the Democratic Party’s nominee, has previously referenced Brown in her public speeches. She referenced him in a January speech to a Women’s Missionary Society of the African Methodist Episcopal Church.

Brown told Sojourners that he invoked his favorite Bible verse, Micah 6:8, as he spoke with Harris, reminding her to “do justice, love mercy, and walk humbly with your maker.”

“That’s what we need in this nation. There’s too much arrogance and egocentricity after all this Trumpism,” he said.

Brown said he has known Harris and her family for more than two decades, calling Harris’ mother “a terrific scholar and scientist.” Harris’s mother, Shyamala Gopalan Harris, was a Hindu from Chennai, India, who worked on breast cancer research. Harris’s father, Donald Harris, is a Black Baptist and a professor emeritus at Stanford University.

Her parents gave her experiences from the Hindu and Baptist traditions when she was growing up. In her 2019 memoir, Harris wrote that her “earliest memories of the teachings of the Bible were of a loving God, a God who asked us to ‘speak up for those who cannot speak for themselves’ and to ‘defend the rights of the poor and needy.’”

.

A composite of Rev. Amos C. Brown and Vice President Kamala Harris. Photo of Brown courtesy Third Baptist Church in San Francisco. Photo of Harris looking on as she speaks at her Presidential Campaign headquarters in Wilmington, Del., July 22, 2024. Erin Schaff/Pool via REUTERS. Composite by Mitchell Atencio/Sojourners

.

.

Click the link below for the article:

.

__________________________________________

Click the link below the picture

.

Fresh research shows that high-paying remote job opportunities are making a comeback—specifically with regards to hybrid remote arrangements.

At the beginning of the year, high-paying hybrid jobs—the roles that pay $250,000 or more—equated to just 1% of total jobs available, reveals the high-paying job platform Ladders in their latest report; while by the second quarter of 2024, high-paying hybrid jobs yielding the same salary comprised nearly 3% of all listings, evidencing positive upward progress.

“It looks like companies that were mostly onsite before are now adopting hybrid setups to attract and retain top talent. They are finding a sweet spot with hybrid work, which many believe offers the flexibility of remote work while preserving the collaborative and leadership benefits of being in the office,” said John Mullinix, Ladders’ director of growth marketing.

14 High-Paying Hybrid Remote Jobs

The same job board highlighted the following high-paying hybrid remote jobs as being the top roles in demand that pay $250,000+ or more on average, from their analysis of half a million job postings from April to June 2024:

1. Physician
2. Medical director
3. Dentist
4. Psychiatrist
5. Principal software engineer
6. Chief Financial Officer (CFO)
7. Relief veterinarian
8. Primary care physician
9. Family medicine physician
10. Solar sales representative
11. Market manager
12. Attending Physician
13. Chief Operating Officer (COO)
14. Enterprise account executive

What Do I Need To Land A High-Paying Hybrid Remote Job?

First, let’s talk about experience levels.

According to the research, to land a high-paying hybrid remote job today, you would need to have between eight to 10 years of experience. But there are also many roles that require between five to seven years of experience, so having a hybrid remote job that pays $250,000 or more is not out of the ordinary for someone earlier in their career.

In terms of education, the roles listed above typically require you to have graduated at a bachelor’s or master’s degree level; however, a few, such as market manager, sales representative, account executive, and even COO, can be achieved even without attending college or university for four years.

.

High-paying hybrid remote job opportunities are on the rise  Getty

.

.

Click the link below for the article:

.

__________________________________________

Click the link below the picture

.

Not long ago, the only way to tell whether a patient with dementia had Alzheimer’s disease was to do an autopsy for the presence of amyloid plaque and other signs of degeneration in the brain. In recent years, new tests can detect the presence of amyloid, a telltale protein of Alzheimer’s, and other biological signs long before the onset of symptoms. Soon, doctors may routinely make definitive diagnoses of Alzheimer’s with a simple blood test, even before symptoms of dementia become apparent. 

An early diagnosis of Alzheimer’s is not worth much if there’s nothing you can do about it. But new effective treatments that slow the progress of the disease have become available: the drug lecanemab, recently approved by the FDA, and a new one called donanemab, which slowed cognitive decline in trials. The availability of effective treatments, together with technologies for detecting Alzheimer’s in the early stages, when those treatments can be most effective, have radically changed the outlook for Alzheimer’s patients and their loved ones. The notion of attacking Alzheimer’s in the brain before clinical symptoms emerge, long merely an aspiration, is starting to look like a practical strategy. 

Advances in early detection and treatment come as welcome news, but they imply a looming public-health challenge. Being able to screen for Alzheimer’s and administer treatments before symptoms arise would vastly increase the number of people who need attention. Public-health institutions are almost universally inadequate for the task. There are large disparities in the impact of Alzheimer’s and in access to care in the U.S. and around the world. Pilot programs in communities around the world are showing how it might be done. 

Meanwhile, the new optimism rippling through the research field is palpable. “Having been in this field for 20 years, the idea that I can finally offer treatments that biologically slow the disease is incredibly exciting,” says Gil Rabinovici, who directs the Alzheimer’s Disease Research Center at the University of California, San Francisco. “There’s a lot more work to do, but the feeling is that our understanding and ability to measure and treat the disease is coming together in a new way.”

An enormous toll

About one in nine Americans over 65 have Alzheimer’s disease, according to figures from the Alzheimer’s Association. The numbers are higher for several segments of the population, including women, Black Americans, and Hispanics. The number of people with Alzheimer’s is expected to more than double in 25 years. 

It is a cruel, relentless disease. “It progressively robs you of who you are,” says neuroscientist Donna Wilcock, director of Indiana University’s Center for Neurodegenerative Disorders. Families carry much of the weight, she adds. The annual cost of Alzheimer’s care in the U.S. has reached $345 billion, the Alzheimer’s Association estimates—and that doesn’t count the $340 billion worth of unpaid care put in by an estimated 11 million family members and other caregivers of U.S. Alzheimer’s patients in 2022. Other estimates run even higher (see “The Ten Trillion Dollar Disease,” on page 24). 

Modern medicine has made enormous strides in treating cancer, diabetes, heart disease, and even other neurodegenerative diseases such as Parkinson’s and multiple sclerosis. But for years, everything medicine could throw at Alzheimer’s seemed to bounce off. The main research strategy has been to try to come up with drugs that attack the plaque that for more than a century has been known to be present in the brain tissue of deceased Alzheimer’s patients. But the dozens of experimental drugs that reduced brain plaque in mice with Alzheimer’s-like symptoms failed to make any detectable difference in cognitive decline in human drug trials. 

.

.

.

Click the link below for the article:

.

__________________________________________

Click the link below the picture

.

Following the news that Adele is taking a break from performing, it sparked a widespread conversation about taking time away from work without being judged.

For many employees —especially women who are not international pop stars —walking away from an income isn’t feasible or supported by employers. And many employees fear how employers could perceive a gap on their resume. I spoke with several experts—all recommend framing a career break in a positive, productive way.

Julia Belak, certified resume writer at Kickresume, shared tips and insights for employees on how to explain gaps or career breaks on your CV, even if you’re not a global superstar. Belak states that there are lots of reasons people might take a career break—from returning from parental leave or other caregiving responsibilities. Or you might have taken some time to travel, or maybe you were looking after your health.

“Whatever the reason, having a recent break on your CV doesn’t mean you aren’t a good candidate,” Belak emphasizes. “It just means you might have to change your strategy a little for your job search. For instance, build a functional CV that opens with a list of your skills rather than with your experience—this lets you show off your relevant skills right from the start.”

She suggests that you make sure you include any additional education or training you might have taken during your break, as well as any new skills you learned. “In the experience section of your CV, just add a line to briefly summarize why you took a career break,” Belak adds. “Be prepared to talk about it in the interview, and don’t worry! Plenty of people have come back after a break and carried on having a successful career.”

Eva Chan, career advisor at Resume Genius, told me by email, “Our Hiring Trends Survey found that 69% of hiring managers are concerned about career gaps, although it wasn’t the biggest red flag.” Chan shares that hiring managers understand the job market has been tough and that life events like a recent layoff can cause career disruptions. “But they still get anxious when seeing employment gaps on resumes,” she admits. “While attitudes toward gaps may have softened slightly, job seekers need to be transparent and present these gaps as times of personal or professional growth. Explain them clearly, and these gaps won’t be a big deal in your job search.”

Chan insists that when addressing a career break on your CV, it’s completely fine to acknowledge that you took some time to recharge and focus on other parts of your life. “Whether you spent time on personal development, caregiving or simply needed to reset and re-prioritize, it’s all about framing your break in a positive and clear way. You don’t have to go into every detail—just focus on what you gained from the experience, whether that’s new skills, personal growth, or volunteering.”Chan suggests that you include a short entry in your CV, explaining the break by highlighting how you stayed productive. “You can easily mention that you used the time off to reset or focus on things like family, health, or passion projects,” she points out. “In your cover letter, you can expand on your career gap more by talking about how you used the time to recharge, learn something new, or focus on family or personal priorities. Framing your CV gaps positively shows hiring managers that your career break was intentional and helped prepare you for the next step in your career. The key is to be honest without oversharing. Keep your explanation professional and emphasize how this break has equipped you to contribute even more in your next role. Employers appreciate transparency, but what they really want to know is how you’re ready to make an impact moving forward.”

.

Adele is taking a break from her singing career for an undisclosed amount of time. What would happen … [+]  Getty Images for AD

.

.

Click the link below for the article:

.

__________________________________________

Click the link below the picture

.

CLIMATEWIRE | A new satellite that can pinpoint greenhouse gas super emitters took off from California on Friday, adding another tool to global efforts to tackle the drivers of global warming.

Tanager-1, which launched alongside SpaceX’s Transporter 11, can detect major emitters of carbon dioxide and methane, a highly potent gas that is 80 times more effective than CO2 at trapping heat in the atmosphere. It was deployed through a coalition involving Carbon Mapper, Planet Labs, and NASA’s Jet Propulsion Laboratory, with funding from groups such as Bloomberg Philanthropies and the Children’s Investment Fund Foundation.

The satellite will focus on facilities that spew out more than 100 kilograms of methane an hour and will help identify the source of those emissions, such as a pipeline leak or flare from a power plant, according to Carbon Mapper. It’s the first of many such satellites the nonprofit hopes to launch, with plans to make the resulting data publicly available online.

Tanager-1 is seen as a complement to MethaneSAT, a satellite supported by the Environmental Defense Fund and Google that helps locate and quantify emissions at a wider scale, such as an entire oil and gas basin.

Riley Duren, Carbon Mapper’s co-founder and chief executive, compared Tanager-1 to a telephoto lens that’s designed to zoom in and identify the origin of emissions within 100 feet, making it easier to see super emitters that might go undetected.

“Super-emitters are potential low hanging fruit for action,” Duren said. “There’s a relatively small number of them. And if you know where they are, you can detect them and you can notify facility operators and notify the regulators — and particularly in cases where there are malfunctions, then there’s the potential to take action.”

Many countries see cutting energy-related methane emissions as among the fastest ways to prevent global temperatures from rising. While methane is more potent than carbon dioxide, it stays in the atmosphere for a shorter time.

More than 150 countries have signed onto a pledge to collectively reduce methane emissions by 30 percent by 2030 and dozens of major oil and gas corporations agreed at last year’s COP28 climate talks to nearly zero out methane emissions by 2030 and end routine flaring.

The White House included Carbon Mapper’s satellite plans in a recent fact sheet outlining government support for action to curb climate super pollutants.

The Tanager-1 satellite will prioritize areas where methane emissions are known to occur, such as oil and gas fields, refineries, and landfills. Carbon Mapper says that information can help companies identify and patch leaks and help countries choose natural gas imports from suppliers with the lowest emissions.

The nonprofit also sees its role as a watchdog, allowing researchers, regulators and green groups to determine whether industries are living up to their emission reduction commitments.

“By improving confidence in the actual methane leakage rates or intensities of global supply chains, we can put pressure on oil and gas producing countries to reduce their methane footprint,” Duren said.

.

.

.

Click the link below for the article:

.

__________________________________________